June 1, 2022

The goal of treatment for Hodgkin lymphoma (HL) in children is similar to that of adults: cure the disease without causing long-term complications. Brentuximab vedotin (Bv) is a CD30-directed antibody-drug conjugate approved for adults with advanced HL. However, studies have found that Bv may also be a safe and effective treatment for children and adolescents with...

Hodgkin lymphoma (HL) is a rare but treatable disease that is curable in around 75% of affected patients. Although the survival of HL has been improved through available treatment options, treatment modalities may cause adverse events and comorbidities that are of particular concern. The cornerstone of therapy for HL includes chemotherapy in combination with radiation...

Pneumocystis jiroveci (PJP) is a severe, opportunistic infection that remains a potential burden in patients who are immunocompromised. Patients who undergo treatment with brentuximab vedotin (BV) may be at risk for this infection due to the CD30-targeted effects of the drug antibody conjugate. Thus, PJP prophylaxis may need to be considered. However, few studies have...

Classical Hodgkin lymphoma (CHL) affects approximately 8,500 new patients each year, and the initial remission rate is over 80%. Previous studies have shown that brentuximab vedotin (BV) and nivolumab (Nivo) are well-tolerated and effective in treating relapsed or refractory (R/R) CHL, but no real-world data are available for this combination of treatments. This study, published...

Immune checkpoint inhibitors (ICIs) block checkpoint proteins from binding with partner proteins, allowing T cells to kill cancer cells. They are safe and effective in treating multiple cancer types, including relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL).  This study, published in the Journal of Clinical Oncology for the 2022 ASCO Annual Meeting, sought to gather long-term...

The implementation of treatment regimens for Hodgkin lymphoma (HL) in the face of COVID-19 is often individualized. Treatments for HL can result in an increased risk of infections and complications due to the immunosuppressive effects of therapy. In addition, standard treatments for HL, including bleomycin and radiation therapy, can increase the risk of pulmonary toxicity....

Racial differences have been observed in the prevalence and presentation of atopic dermatitis in African American and European American patients. African Americans tend to present with extensive papular lesions and widespread extensor surface involvement, as well as lichenification secondary to treatment resistance. Few studies have been conducted on the immune signatures that may drive disease,...

Atopic dermatitis is a common skin condition that severely and negatively affects the quality of life of children and their parents. However, children of Black and Hispanic parents tend to experience persistent and poorly controlled symptoms of atopic dermatitis, which can increase the burden on the quality of life of families of color. In addition,...

Barriers to health care for atopic dermatitis (eczema) and asthma may differ among racial/ethnic minority groups. However, research is limited on the perceptions of these groups regarding access to care. Racial/ethnic minority groups may experience a greater treatment burden and more barriers to appropriate care than other groups. Researchers conducted an online survey across the...